Introduction
============

The coordinated growth-related changes of various components of the eye are required to achieve and maintain emmetropia (the ideal refractive state). During this process of regulated ocular growth, the axial length (distance along the visual axis between cornea and retina) is a critical determinant of refractive status \[[@r1],[@r2]\]. Disruption in the regulation of ocular growth results in the development of refractive error. It is now widely accepted that both environmental and genetic influences contribute to refractive error development. Recently, four independent mutations were identified in the membrane-type frizzled-related protein (*MFRP*) gene associated with nanophthalmos, a rare disorder of eye development characterized by extreme hyperopia (farsighted refractive error) \[[@r3]\]. Mutations in the *MFRP* gene have also been reported in a distinct autosomal recessive ophthalmic syndrome characterized by microphthalmos, retinitis pigmentosa, foveoschisis, and optic disc drusen \[[@r4]\].

*MFRP* is a gene that is selectively expressed in the retinal pigment epithelium (RPE) and ciliary body \[[@r3]\] and encodes a transmembrane receptor protein that contains a cysteine-rich domain (CRD) \[[@r5]\]. CRDs are binding motifs for wingless-type proteins (WNTs), a family of cell signaling molecules that mediate cell growth, differentiation, and development, and along with frizzled proteins, are implicated in eye development and disease (\[[@r6]\] for a detailed review). While Ayala-Ramirez et al. \[[@r4]\] stated that the *MFRP* gene is necessary for photoreceptor maintenance due to the severe rod-cone dystrophy of their patients, Sundin et al. \[[@r3]\] maintained that *MFRP* is not critical for retinal function. However, Sundin et al. \[[@r3]\] proposed a role for *MFRP* in the regulation of ocular axial length.

High hyperopia, microphthalmia, anophthalmia, and high myopia are all ocular disorders that present with altered ocular axial length. While microphthalmia and anophthalmia with very high hyperopia are rare and extreme phenotypes \[[@r7]\], moderate to high hyperopia \[[@r8]\] and high myopia (\[[@r9]\] for a detailed review) are relatively more prevalent. All of these conditions with high degrees of refractive error potentially result in secondary complications and visual loss. High degrees of hyperopia are associated with a narrow angle between the iris and cornea, an expansion of the choroidal vascular bed, choroidal folds, and thickened sclera \[[@r10]--[@r12]\] and can lead to angle closure glaucoma and retinal detachment (RD). High myopia is frequently associated with cataract, glaucoma, retinal detachment, and posterior staphyloma with retinal degenerative changes including choroidal neovascularization \[[@r13],[@r14]\]. In addition to pathology leading to visual loss, refractive error prevalence has a high public health and economic impact \[[@r15]\], thus, it is important to understand ocular growth regulation in refractive error development.

We hypothesized that the *MFRP* gene is important in the ocular axial length regulation of all types. In this study, we screened for sequence variants in the *MFRP* gene and tested for genetic association in moderate to high hyperopic, non-syndromic microphthalmic or anophthalmic, and non-syndromic high myopic patients. We sought to investigate whether sequence variants of *MFRP* are associated with less severe forms of hyperopia, other extreme forms of limited eye growth and development or high myopia and whether the *MFRP* gene plays a role in regulating ocular axial length in general.

Methods
=======

Patient information
-------------------

Informed consent was obtained from all participants, and total genomic DNA was extracted from venous blood using AutoPure LS^®^ DNA Extractor and PUREGENE™ reagents (Gentra Systems Inc., Minneapolis, MN). The study was approved by the Institutional Review Board at Duke University and followed the principles of the Declaration of Helsinki. Eleven moderate to high hyperopic subjects, 10 microphthalmic/anophthalmic patients, 11 control subjects, and seven high-grade myopic subjects of varying ages participated in the sequencing study. A large data set comprising of 146 multiplex families that included 634 subjects was used for the genotyping study. Those with systemic conditions and syndromic disorders that could predispose them to their refractive status were ruled out by an ophthalmic physician and geneticist if necessary.

Primers
-------

The *MFRP* gene maps to chromosome 11q23.3 and spans the distance between genomic positions 118716837 and 118722580 (UCSC genome browser - Human Mar. 2006 \[hg18\] assembly). It is composed of 13 exons, and its genomic structure is detailed in [Figure 1](#f1){ref-type="fig"}. Sixteen primer pairs were designed to amplify the identified 13 exons including the 5′ and 3′ untranslated regions (covering 50--150 base pairs \[bp\] of each intron-exon boundary; [Table 1](#t1){ref-type="table"}).

![Schematic representation of the genomic arrangement of *MFRP* on chromosome 11q23.3. The vertical boxes represent exons, the horizontal bars represent introns, and the arrow heads represent the direction of transcription (source; UCSC genome browser).](mv-v14-387-f1){#f1}

###### *MFRP* gene primers for sequence variants' screening.

  **Exon**      **5′-3′ Sequence**          **Fragment size (bp)**   **Chromosomal location**
  ------------- --------------------------- ------------------------ --------------------------
  Exon1_F       CAGCTGAGTTGGATTAAGGGAC                               118722259
  Exon1_R       AGACTCAGGCTCGAAGGCAG        435                      118722693
  Exon2_F       CTTGTGCCATGAAGGACTTCTC                               118722013
  Exon2_R       CTGGAGAGCAGGAGGACACAG       429                      118722441
  Exon3_F       CAGCTCCCTGGCATGGTAAC                                 118721847
  Exon3_R       CTCTGGAGGCGAGAAGATGG        360                      118722206
  Exon4_F       CTTCTCCTGGCTCTGTGTCC                                 118721553
  Exon4_R       GCTGCAGAGATGGAGGTTAGAG      493                      118722045
  Exon5_F       ACAGTCCAGTGAGTACTGGGG                                118721219
  Exon5_R       CCCAGAGGTCTAGTCTCTCAATTTC   482                      118721700
  Exon6_F       AGAGCTCCCTGGGACATCAG                                 118720655
  Exon6_R       GAACTCATCATGGGCACAGC        419                      118721073
  Exon7_F       GGTGAGTGTGTTCCCACCTG                                 118720437
  Exon7_R       GACTGAGCAGGAAATGCTGAC       358                      118720794
  Exon8_F       CTTTGGCCCAGAACTTGTTTC                                118720107
  Exon8_R       CCGTCTGCTTGATCTCTGACC       327                      118720433
  Exon9_F       TGAAACCAGGTAAATTAAAGGTCC                             118719592
  Exon9_R       TTAGGGTGATGGTGAAGAGACC      447                      118720038
  Exon10_F      CAGACCCTAACCCTGTGTCTTC                               118718595
  Exon10_R      CACACCCTTACACCCTCCTG        465                      118719059
  Exon11_F      AATGCCACGGAGAGTAGGTG                                 118718370
  Exon11_R      GTGAAGTGGTCCCAGAGTCAG       436                      118718805
  Exon12_F      ATCCTCTTGCTTCCTCACAACC                               118717661
  Exon12_R      AAATGCTGGTAGCAGGGCAG        374                      118718034
  Exon13_1\_F   AGGAGGTGGTAGAGGTCCTCAG                               118717426
  Exon13_1\_R   AAAAGAGGACGGGCAGGAAG        383                      118717808
  Exon13_2\_F   CACCCCACTAGGCAGTGTTC                                 118717141
  Exon13_2\_R   ATCAAGGAAAAGGTCAGAAGGC      484                      118717624
  Exon13_3\_F   GGGGAAGAGAAGTCCTCAGC                                 118716989
  Exon13_3\_R   CAGTGGCAGAGACCAAGGAC        353                      118717341
  Exon13_4\_F   GCATCTATTCATGTGGCAGGC                                118716657
  Exon13_4\_R   TACTCCGGACCCTCCAGTTG        466                      118717122

Sixteen primer pairs were designed to amplify all 13 exons of the *MFRP* gene covering 50--150 bp of each intron-exon boundary. "F" and "R" represent the forward and reverse primers, respectively. 'bp' -- base pairs.

Sequencing analyses
-------------------

Polymerase chain reactions (PCRs) were performed on genomic DNA using Platinum® Taq DNA polymerase (Invitrogen Corporation, Carlsbad, CA) using a touchdown protocol (available upon request). Amplicons were visualized by means of agarose gel electrophoresis and were purified with Quickstep™ 2 SOPE™ Resin (Edge BioSystems, Gaithersburg, MD). Sequencing reactions were performed using BigDye™ Terminator on ABI3730 or 3100 Genetic Analyzer (Applied Biosystems Inc., Foster City, CA). Sequences were trimmed for quality and aligned using Sequencher™ (Gene Codes, Ann Arbor, MI). Individual DNA sequences were compared alongside the known reference sequence for *MFRP* (UCSC genome browser, Representative Refseq: [NM_031433](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=031433)).

Genotyping
----------

Seventeen single nucleotide polymorphisms (SNPs) were chosen to cover the *MFRP* gene and its flanking regions. We applied SNPSelector^®^ \[[@r16]\] to select tagging SNPs that met the following two criteria: (1) a Pearson correlation (r^2^) of at least 0.67 in the linkage disequilibrium (LD) bins and (2) a minor allele frequency of at least 5% in the Caucasian population. The SNPs that were chosen were [rs2509656](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2509656), [rs11217240](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217240), [rs11217241](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217241), [rs669462](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=669462), [rs948413](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=948413), [rs948414](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=948414), [rs10790289](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10790289), [rs12294677](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12294677), [rs12421909](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12421909), [rs883247](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883247), [rs883245](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883245), [rs3814758](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3814758), [rs12577147](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12577147), [rs11217244](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217244), [rs7932692](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7932692), [rs10892353](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10892353), and [rs7122785](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7122785). A custom TaqMan^®^ allelic discrimination assay, which consisted of a mix of unlabeled PCR primers and the TaqMan^®^ minor groove binding group (MGB) probe (FAM™ and VIC^®^ dye-labeled; Applied Biosystems Inc.), was used. This assay comprised of two unlabeled PCR primers and two allele-specific probes. PCR reactions were performed with the Taqman^®^ Universal PCR Master Mix on GeneAmp^®^ PCR System 9700 (Applied Biosystems Inc.), and the ABI7900HT Fast PCR System (Applied Biosystems Inc.) was used for reading the allelic discrimination calls.

Statistical analyses
--------------------

For sequencing data, all SNPs were tested for association using the Fisher Exact Test with a significance level threshold of 0.05. For genotyping data, family-based Pedigree Disequilibrium Test (PDT) and Genotype Pedigree Disequilibrium Test (GenoPDT) were used to test for the association of markers in groups comprising of high myopes (≤5.00 D) and moderate-high hyperopes (≥+2.00 D) in comparison to control subjects (between +0.50 and −0.50 D).

Results
=======

For the patient samples used for direct sequencing, the average spherical refractive error of the hyperopic patient group was +4.21 diopters (D; range +2.00 to +9.25 D) and of the myopic patient group was −12.36 D (range −8.25 to −14.50 D). The refractive status findings for the hyperopic and myopic patients are listed in [Table 2](#t2){ref-type="table"}.

###### Refractive status (sphere) findings of hyperopic and myopic subjects.

  **Moderate-high hyperopic subjects**   **Refractive status OD (Diopters)**   **Refractive status OS (Diopters)**
  -------------------------------------- ------------------------------------- -------------------------------------
  1                                      +8.00                                 +9.25
  2                                      +4.25                                 +4.00
  3                                      +8.00                                 +9.25
  4                                      +2.00                                 +2.00
  5                                      +2.00                                 +2.25
  6                                      +5.25                                 +3.75
  7                                      +3.25                                 +2.25
  8                                      +2.75                                 +3.00
  9                                      +2.25                                 +3.25
  10                                     +2.50                                 +2.50
  11                                     +7.75                                 +3.25
  **High myopic subjects**               **Refractive status OD (Diopters)**   **Refractive status OS (Diopters)**
  12                                     −14.25                                −14.5
  13                                     −8.25                                 −7.875
  14                                     −13.75                                −13.625
  15                                     −11.00                                −9.875
  16                                     −11.50                                −11.375
  17                                     −14.50                                −13.50
  18                                     −13.25                                −14.00

Moderate to high hyperopic and high myopic patients were screened for MFRP sequence variants. Refractive error was measured using streak retinoscopy to the closest 0.25 diopters (D).

A total of 16 SNPs were identified by direct sequencing. A synonymous SNP ([rs36015759](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=36015759)) in exon 5 was observed in six hyperopic (five heterozygous, one substitution), six microphthalmic/anophthalmic, two high myopic, and five control subjects (all heterozygous). Five other known SNPs ([rs883245](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883245) and [rs883247](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883247) in the 5′ UTR, [rs3814762](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3814762) in exon 4, [rs2510143](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2510143) in exon 5, and [rs948411](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=948411) in intron 9) were observed in the hyperopic, microphthalmic/anophthalmic, and high-grade myopic patients as well as the control subjects (see [Table 3](#t3){ref-type="table"} for details). In addition, 10 isolated, novel SNPs were identified in exons 5 (synonymous), 6 (non-synonymous), 8 (synonymous), 9 (non-synonymous), and 13 (3′ UTR) as well as in introns 8 and 11. No significant association was obtained for any SNP with any of the phenotypes studied. In addition, the family-based association study using a larger set of family data did not reveal any significant association of markers genotyped with either the hyperopic or myopic groups when compared to the control group. The results obtained from the family-based association PDT and GenoPDT analyses are listed in [Table 4](#t4){ref-type="table"}.

###### Sequence variants observed in the *MFRP* gene by direct sequencing in various phenotypes studied.

  ---------------------- ------------------------------------------- -------------------------- ----------------------- --------------------------------------------------------------------------------------- ----------------------- ---- --- ----
  ***MFRP* gene**        **Location on Chromosome 11 (base pair)**   **Nucleotide change(s)**   **Amino acid change**   **dbSNP (rs\#)**                                                                        **Subject phenotype**            
  **Hyperopia (n=11)**   **Microphthalmia (n=10)**                   **High Myopia (n=7)**      **Controls (n=11)**                                                                                                                              
  Exon 1                 118722521                                   C/T, C-\>T (sub)                                   [rs883245](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883245)  (5′ UTR)             11                      8    7   8
                         118722464                                   A/G,G-\>A (sub)                                    [rs883247](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883247)  (5′ UTR)             11                      8    7   7
  Exon 4                 118721714                                   A/G,G-\>A (sub)            Val-\>Met               [rs3814762](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3814762)  (non-synonymous)   6                       5    5   7
  Exon 5                 118721489                                   T/C,C-\>T (sub)                                    [rs36015759](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=36015759)  (synonymous)     6                       6    2   5
                         118721441                                   C/T,T-\>C (sub)                                    [rs2510143](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2510143)  (synonymous)       11                      10   6   11
  Exon 6                 118720829                                   A/G                        Met-\>Val               Novel (non-synonymous)                                                                  1                       0    0   0
  Intron 8               118720229                                   A/C                                                Novel                                                                                   2                       0    2   1
                         118720230                                   C/T                                                Novel                                                                                   0                       0    0   1
  Exon 8                 118720283                                   G/A                                                Novel                                                                                   0                       0    2   0
                         118720256                                   A/G                                                [rs35885438](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=35885438)  (synonymous)     0                       1    0   0
  Exon 9                 118719814                                   A/G                        Val-\>Met               Novel (non-synonymous)                                                                  1                       0    0   0
  Intron 9               118718992                                   A/T                                                [rs948411](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=948411)                       4                       3    2   2
  Intron 11              118718544                                   A/G                                                Novel                                                                                   1                       1    0   0
  Exon 11                118718539                                   G/T                        Ser-\>Iso               Novel (non-synonymous)                                                                  0                       0    0   1
                         118718513                                   A/G                                                [rs11217241](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217241)  (synonymous)     0                       0    1   2
  Exon 13                118717345                                   A/G                                                Novel (3′ UTR)                                                                          1                       0    0   0
  ---------------------- ------------------------------------------- -------------------------- ----------------------- --------------------------------------------------------------------------------------- ----------------------- ---- --- ----

Six novel and 7 known single nucleotide polymorphisms (SNPs) were identified with sequence variant screening. None were associated with any of the phenotypes studied. The "rs" number refers to the reference cluster number of the polymorphism.

###### Family-based association Pedigree Disequilibrium Test (PDT) and GenoPDT analyses.

  ----------------------------------------------------------------------- -------------- ----------------------------------------------------- ------------------------------------------------------ ------ ------
  **Markers**                                                             **Position**   **Hyperopia (\>+2D) versus Normal (−0.5 to +0.5D)**   **High Myopia (≤-5D) versus Normal (−0.5 to +0.5D)**          
  **PDT**                                                                 **GenoPDT**    **PDT**                                               **GenoPDT**                                                   
  [rs2509656](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2509656)     118713786      1.00                                                  1.00                                                   0.42   0.55
  [rs11217240](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217240)   118715126      1.00                                                  1.00                                                   1.00   1.00
  [rs11217241](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217241)   118718513      0.31                                                  0.32                                                   0.25   0.25
  [rs669462](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=669462)       118718715      1.00                                                  1.00                                                   1.00   1.00
  [rs948413](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=948413)       118719981      0.41                                                  0.41                                                   0.34   0.27
  [rs948414](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=948414)       118720008      0.32                                                  0.32                                                   0.63   0.35
  [rs10790289](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10790289)   118720375      0.37                                                  0.37                                                   0.59   0.86
  [rs12294677](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12294677)   118721107      1.00                                                  1.00                                                   1.00   1.00
  [rs12421909](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12421909)   118721111      0.24                                                  0.4                                                    0.36   0.47
  [rs883247](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883247)       118722464      0.18                                                  0.48                                                   0.14   0.42
  [rs883245](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=883245)       118722521      0.31                                                  0.31                                                   0.24   0.4
  [rs3814758](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3814758)     118723028      0.18                                                  0.48                                                   0.42   0.75
  [rs12577147](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12577147)   118723858      0.32                                                  0.32                                                   0.07   0.21
  [rs11217244](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11217244)   118723994      1.00                                                  1.00                                                   1.00   1.00
  [rs7932692](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7932692)     118725222      0.18                                                  0.48                                                   0.58   0.87
  [rs10892353](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10892353)   118726659      0.32                                                  0.51                                                   0.54   0.78
  [rs7122785](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7122785)     118727916      0.18                                                  0.48                                                   0.71   0.18
  ----------------------------------------------------------------------- -------------- ----------------------------------------------------- ------------------------------------------------------ ------ ------

p-values obtained from both tests for all the markers are listed. No significant association of markers was revealed with either the hyperopic or myopic groups when compared to the control group. D--diopters.

Discussion
==========

There is strong evidence for a heritable effect for high hyperopia \[[@r17],[@r18]\], microphthalmia \[[@r19],[@r20]\], and high myopia \[[@r9]\]. The *MFRP* gene is predominantly expressed in the eye and at low levels in the brain \[[@r5],[@r21]\], and its selective expression in the RPE makes it an ideal candidate gene for the proposed role in axial length regulation. During ocular axial length regulation, a retino-scleral signaling cascade has been postulated to explain the changes in the scleral structure and composition \[[@r22]\]. The RPE layer has been proposed to transmit these signals \[[@r23]\]. Furthermore, the potential for MFRP interactions (via the cysteine-rich domain) with WNT proteins is suggestive of a role in eye development and disease.

In this study, mutation screening of the *MFRP* gene revealed no sequence variants that would implicate this gene in the development of moderate to high hyperopia, isolated microphthalmia, isolated anophthalmia, or high-grade myopia. In addition, we presented a family-based association study of SNPs on the *MFRP* gene using a large family data set. We did not identify any significant association results for *MFRP* markers in moderate to high hyperopia and high-grade myopia phenotypes. The family-based association tests applied to this study are known to be robust against population stratification and appropriate for multiplex families such as those screened in this study \[[@r24],[@r25]\].

Our results indicate that the *MFRP* gene may not be primarily involved in ocular axial length regulation. It is possible that *MFRP* performs a different role in disorders such as isolated nanophthalmos and syndromic microphthalmia (where mutations have been reported) both of which are recognized as developmental disorders unlike hyperopia and myopia. Although the microphthalmia/anophthalmia cohort in this study could be considered developmental, we did not observe any mutations in the *MFRP* gene in this cohort. However, isolated microphthalmia and anophthalmia (unlike syndromic) have been previously attributed to mutations in the retinal homeobox gene (CHX10) \[[@r26],[@r27]\], which is in concurrence with the current findings, and future studies are needed to confirm this line of thought.

No mutations were observed in exons 5 and 10, which housed the previously reported *MFRP* gene mutations that resulted in a mutant protein \[[@r3],[@r4]\]. However, we observed some coding synonymous (silent) single nucleotide polymorphisms (SNPs) in exon 5 in six hyperopic and six microphthalmic/anophthalmic subjects (approximately 60%) in our sequencing data. While studies on the effect of silent SNPs on protein structure are still emerging, there is a new line of thought that silent SNPs can affect in vivo protein folding and function by altering translation kinetics \[[@r28],[@r29]\]. Further studies are needed to prove this; however, if this is the case, there could be a potential role for the silent SNPs in the *MFRP* gene reported in this study and future research should take these findings into account.

Another possibility is that proteins that interact with the *MFRP* gene could be involved in the regulation of ocular axial length. It is reasonable to state that regulation of eye size is a complex process and is likely to involve multiple genes. While the previously reported *MFRP* mutations in isolated nanophthalmos and syndromic microphthalmia may not directly influence axial length programming, the resultant loss of *MFRP* interaction involved in axial length regulation could lead to reduced eye size in those phenotypes.

In conclusion, sequence variants of the *MFRP* gene do not appear to be associated with either the less severe forms of hyperopia, extreme forms of limited eye growth and development, or high myopia. Our findings indicate that *MFRP* is not primarily and directly involved in ocular axial length regulation. Future studies revealing gene mutations in disease phenotypes with altered ocular axial length and the relationship of *MFRP* with these mutant genes will shed more light on the precise role of *MFRP*.
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